Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7056
Source ID: NCT04032197
Associated Drug: Semaglutide
Title: A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: Semaglutide|DRUG: Placebo (semaglutide)
Outcome Measures: Primary: Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries, Ratio, From baseline (from 41 days before randomisation) to week 26 | Secondary: Change in maximum target-to-background ratio (TBR) for 68Ga-DOTATATE in the carotid arteries, Ratio, From baseline (from 40 days before randomisation) to week 26|Change in total wall volume of the most diseased carotid artery, mm3, From baseline (from 41 days before randomisation) to week 52|Change in lipid rich necrotic core (LRNC) volume of the atherosclerotic plaque in the most diseased carotid artery, mm3, From baseline (from 41 days before randomisation) to week 52|Change in average fibrous cap thickness (FCT) of the atherosclerotic plaque in the most diseased carotid artery, mm, From baseline (from 41 days before randomisation) to week 52
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE1
Enrollment: 101
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2019-08-12
Completion Date: 2023-06-06
Results First Posted:
Last Update Posted: 2024-05-03
Locations: Clinical Trials Unit / Center for Medical Research, Graz, 8010, Austria|Steno Diabetes Center Copenhagen, Herlev, 2730, Denmark|Karolinska Universitetssjukhuset Solna,FOU Tema Hjärta Kärl, Stockholm, 171 76, Sweden|CTC Clinical Trial Consultants AB, Uppsala, Uppsala, 75237, Sweden
URL: https://clinicaltrials.gov/show/NCT04032197